Clinical value of combined detection of GP73,AFP-L3 and TGFβ1 in early diagnosis of hepatocellular carcinoma
10.3969/j.issn.1673-4130.2014.14.010
- VernacularTitle:GP73、AFP-L3和 TGFβ1联合检测在肝细胞癌早期诊断中的临床价值
- Author:
Weili XIAO
;
Si HA
;
Zhihong REN
;
Chengling YAN
;
Haitao DING
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
Golgi membrane protein;
alpha-fetoprotein variant-L3;
transforming growth factor beta 1
- From:
International Journal of Laboratory Medicine
2014;(14):1839-1841
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of the combined detection of Golgi protein 73 (GP73),alpha-fetoprotein variant-L3 (AFP-L3)and transforming growth factorβ1(TGFβ1)in the early diagnosis of hepatocellular carcinoma (HCC).Meth-ods 48 cases of healthy control,42 cases of hepatitis B,50 cases of posthepatitic cirrhosis and 58 cases of HCC were selected and detected GP73,AFP-L3 and TGFβ1.The detection results were compared among 4 groups.Results (1)The levels of GP73,AFP-L3 and TGFβ1 had statistical differences among 4 groups(P <0.05 );(2 )The positive rate of the 3-marker combined detection reached 96.55%,which was higher than that of the 2-marker combined detection and the single marker detection.Conclusion (1) GP73,AFP-L3 and TGFβ1 may be used as the serum indicators for the early diagnosis of HCC;(2)Compared with the traditional HCC marker AFP,AFP-L3 has relatively high sensitivity and specificity and has the important role in the differential diagnosis of benign and malignant diseases of the liver,which is considered as a better serum marker in the HCC diagnosis;(3)The 3-indicator combined detection can significantly improve the positive detection rate of HCC and has better application value.
